The potential reassessment of cannabinoids, particularly at the federal level, is generating considerable anticipation within the industry. A shift away from Schedule I status, often viewed as outdated and hindering innovation, could unlock significant avenues for ventures. Reduced regulatory impediments, alongside greater access to banking and fun